QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=18A6E535F8253C80572B1F5ACAEBD5AC;jsessionid=4535FD7B0284BE655FA39BA9A4830C2E;jsessionid=C4507C72F3FF42F78CCE34911DC157AF;jsessionid=BBCB675B0BD806D402B7AA5F3E607922;jsessionid=4C08C50263016A83CB3F394FA365B545 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
4. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.
5. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=18A6E535F8253C80572B1F5ACAEBD5AC;jsessionid=4535FD7B0284BE655FA39BA9A4830C2E;jsessionid=C4507C72F3FF42F78CCE34911DC157AF;jsessionid=BBCB675B0BD806D402B7AA5F3E607922;jsessionid=4C08C50263016A83CB3F394FA365B545